Updated Trial and Real-World Data Show Benefit of Ide-Cel for Multiple Myeloma

Now Viewing

EP: 1.Updated Trial and Real-World Data Show Benefit of Ide-Cel for Multiple Myeloma

EP: 2.Ide-Cel Shows Benefit for Multiple Myeloma After 2 to 4 Lines of Therapy

EP: 3.CAR T-Cell Therapy Significantly Impacts R/R Multiple Myeloma

EP: 4.How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma

EP: 5.Ide-cel Shows Efficacy Earlier in R/R Multiple Myeloma Despite Crossover

EP: 6.Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

EP: 7.Referral for CAR T Should Always Be Considered in R/R Multiple Myeloma

EP: 8.CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma

EP: 9.Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers

Abdullah M. Khan, MBBS, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – The James, discusses the recent updates to data on the use of idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory multiple myeloma.

Updated data from the pivotal phase 3 KarMMa-3 trial (NCT03651128), which led to the approval of this chimeric antigen receptor T-cell therapy, were reported at the 2023 American Society of Hematology Annual Meeting & Exposition. At a follow-up of 30.9 months, investigators reported interim overall survival (OS) data, showing that the median OS was 41.4 months with ide-cel vs 37.9 months in the standard therapy group.

Additionally, Khan noted that real-world evidence with ide-cel was reported in the Journal of Clinical Oncology in 2023, supporting its use in patients who do not necessarily match the stringent patient eligibility requirements of a clinical trial. For the 159 patients who received ide-cel, the best overall response rate was 84% and median progression-free survival (PFS) was 8.5 months (95% CI, 6.5-not reached), whereas median OS was 12.5 months (95% CI, 11.3-not reached).

According to Khan, these are both promising sources of data showing the benefit of ide-cel including in patients with comorbidities who are treated with CAR T-cell therapy in the real world.

TRANSCRIPTION:

0:08 | I wanted to give a little bit of updated data from the ASH 2023 conference. We actually have survival data for the KarMMa-3 trial with a longer follow-up of about 31 months. What they were able to show was the median OS in the ide-cel group was 41.4 months vs 37.9 months in the standard [therapy] group.

0:38 | There was also recent publication talking about ide-cel in the real world. Real world means that inclusion and exclusion criteria that are pretty stringent in trial design, we're applying less of those rules toward the patients we see in our clinic. And in a recent publication in JCO in 2023, in 159 patients, what they showed was response rates were also very impressive, about 84%. …In these less ideal patients…in terms of trial candidacy, median PFS was 8.5 months, and the median OS was 12.5 months. Again, very promising data, not just in the trial, but also real-world data.